An Open‐Label, Single‐Arm, Phase II Study of Pertuzumab With High‐Dose Trastuzumab for the Treatment of Central Nervous System Progression Post‐Radiotherapy in Patients With HER2‐Positive Metastatic Breast Cancer (PATRICIA). This evidence concerns the gene ERBB2 and breast carcinoma.